EPS for Spectrum Pharmaceuticals, Inc. (SPPI) Expected At $-0.28

April 25, 2018 - By Stephen Andrade

Investors sentiment decreased to 1.63 in 2017 Q4. Its down 1.21, from 2.84 in 2017Q3. It dropped, as 26 investors sold Spectrum Pharmaceuticals, Inc. shares while 28 reduced holdings. 27 funds opened positions while 61 raised stakes. 78.22 million shares or 9.25% more from 71.60 million shares in 2017Q3 were reported.
Fny Managed Accounts Ltd Com accumulated 763 shares. Blackrock has 0.01% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Amalgamated Bank & Trust reported 0.01% of its portfolio in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Parallax Volatility Advisers L P has invested 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Public Sector Pension Investment Board has invested 0.01% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Moreover, Amer Group has 0% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) for 69,531 shares. Fmr Ltd Liability Com holds 7.04 million shares or 0.02% of its portfolio. Clarivest Asset Ltd Liability Corporation reported 0.08% stake. Envestnet Asset Mngmt has 3,690 shares for 0% of their portfolio. Opaleye Mngmt Incorporated, Massachusetts-based fund reported 31,000 shares. Prudential Finance, a New Jersey-based fund reported 146,991 shares. Jpmorgan Chase reported 287,965 shares or 0% of all its holdings. Numeric Invsts Limited Liability invested in 344,168 shares or 0.05% of the stock. Parkside Finance Bancorp & Tru reported 77 shares. Swiss Bancshares stated it has 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).

Since March 21, 2018, it had 0 insider buys, and 16 insider sales for $8.86 million activity. 90,000 shares valued at $1.83 million were sold by SHROTRIYA RAJESH C MD on Wednesday, April 11. GUSTAFSON KURT A sold $22,594 worth of stock or 1,300 shares. Riga Thomas J sold $107,603 worth of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) on Monday, April 16. Another trade for 4,200 shares valued at $78,278 was sold by Krassner Stuart Mitchell.

Analysts expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report $-0.28 EPS on May, 1.They anticipate $0.10 EPS change or 55.56 % from last quarter’s $-0.18 EPS. After having $-0.29 EPS previously, Spectrum Pharmaceuticals, Inc.’s analysts see -3.45 % EPS growth. The stock decreased 5.04% or $0.92 during the last trading session, reaching $17.34. About 1.04M shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has risen 143.80% since April 25, 2017 and is uptrending. It has outperformed by 132.25% the S&P500.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage

Among 2 analysts covering Spectrum Pharmaceuticals (NASDAQ:SPPI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharmaceuticals had 3 analyst reports since December 18, 2017 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, April 10 by FBR Capital.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $1.76 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: